Zai Lab (HKG:9688) said patients responded well to its lung cancer treatment, Zoci, in combination with other drugs during a global phase 1b study, according to a Friday bourse filing.

The biopharma company said patients with extensive-stage small cell lung cancer, who received Zoci plus atezolizumab achieved a confirmed objective response rate (ORR) of 81.8%, while the ORR was 92.3% in those who received the drug with atezolizumab and carboplatin.

Zai Lab said it will present the findings from the study at the European Society for Medical Oncology Congress 2026 in Madrid, Spain, and plans to initiate a global phase 3 trial of its drug along with an immuno-oncology regimen by the end of the year.

Shares were up nearly 4% in Monday's late-morning trading.